{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0018908,73,MONDO:0018908,192,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0018908","source":"MONDO:0018908|non-Hodgkin lymphoma","targets":["NCT00090038|Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma|COMPLETED|PHASE4|INTERVENTIONAL","NCT00162955|Prevention of CHOP-induced Chronic Cardiotoxicity|COMPLETED|PHASE4|INTERVENTIONAL","NCT00277160|A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer|COMPLETED|PHASE4|INTERVENTIONAL","NCT00352703|PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation|COMPLETED|PHASE4|INTERVENTIONAL","NCT00430352|MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.|COMPLETED|PHASE4|INTERVENTIONAL","NCT00797810|Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00969462|Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma|COMPLETED|PHASE4|INTERVENTIONAL","NCT01164475|Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms|COMPLETED|PHASE4|INTERVENTIONAL","NCT01180049|Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma|COMPLETED|PHASE4|INTERVENTIONAL","NCT02782845|An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)|COMPLETED|PHASE4|INTERVENTIONAL","NCT05191225|Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06665737|Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT06876649|A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib|RECRUITING|PHASE4|INTERVENTIONAL","NCT06876662|A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma|RECRUITING|PHASE4|INTERVENTIONAL","NCT00039910|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia|COMPLETED|PHASE3|INTERVENTIONAL","NCT00057343|Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT00078598|A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00091676|Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00129090|Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00133302|Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)|TERMINATED|PHASE3|INTERVENTIONAL","NCT00139841|Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab|COMPLETED|PHASE3|INTERVENTIONAL","NCT00152139|Stem Cell Transplantation for Patients With Hematologic Malignancies|COMPLETED|PHASE3|INTERVENTIONAL","NCT00269113|A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00312845|Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00352846|Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss|COMPLETED|PHASE3|INTERVENTIONAL","NCT00398411|Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells|COMPLETED|PHASE3|INTERVENTIONAL","NCT00463463|Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00469729|Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00491491|Zevalin-beam for Aggressive Lymphoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00577161|Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT00719472|A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00877006|Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study|COMPLETED|PHASE3|INTERVENTIONAL","NCT00877214|Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT00928018|Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00991211|Bendamustine Plus Rituximab Versus CHOP Plus Rituximab|COMPLETED|PHASE3|INTERVENTIONAL","NCT01021423|A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).|TERMINATED|PHASE3|INTERVENTIONAL","NCT01059630|A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01073163|Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01085058|Predictive Value of the Cytocapacity Test Patients With Lymphoproliferative Diseases and High-dose Therapy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01103388|Rituximab Maintenance After Autologous Transplantation|TERMINATED|PHASE3|INTERVENTIONAL","NCT01144364|A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01200589|Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy|TERMINATED|PHASE3|INTERVENTIONAL","NCT01200758|A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01332968|A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01456351|Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab|COMPLETED|PHASE3|INTERVENTIONAL","NCT01461928|A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab|COMPLETED|PHASE3|INTERVENTIONAL","NCT01596621|A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment|COMPLETED|PHASE3|INTERVENTIONAL","NCT01597778|Double Cord Versus Haploidentical (BMT CTN 1101)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01767714|Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation|COMPLETED|PHASE3|INTERVENTIONAL","NCT01777152|ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas|COMPLETED|PHASE3|INTERVENTIONAL","NCT01854567|P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies|COMPLETED|PHASE3|INTERVENTIONAL","NCT01951885|Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention|COMPLETED|PHASE3|INTERVENTIONAL","NCT02186574|Tenofovir to Prevent HBV Reactivation|UNKNOWN|PHASE3|INTERVENTIONAL","NCT02406092|Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A|COMPLETED|PHASE3|INTERVENTIONAL","NCT02566395|Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies|COMPLETED|PHASE3|INTERVENTIONAL","NCT02722733|Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT03570892|Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03844048|An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04459416|Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05171647|A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05645107|A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma|RECRUITING|PHASE3|INTERVENTIONAL","NCT05664217|NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT06520163|Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma|RECRUITING|PHASE3|INTERVENTIONAL","NCT07188558|A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy|RECRUITING|PHASE3|INTERVENTIONAL","NCT07202052|Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT00001379|Treatment and Natural History Study of Lymphomatoid Granulomatosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT00003500|Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00003501|Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00005803|Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00022932|Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP|UNKNOWN|PHASE2|INTERVENTIONAL","NCT00038545|A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00041730|Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma|UNKNOWN|PHASE2|INTERVENTIONAL","NCT00042666|A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.|COMPLETED|PHASE2|INTERVENTIONAL","NCT00043459|Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.|TERMINATED|PHASE2|INTERVENTIONAL","NCT00044902|Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00048555|Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00051025|Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00051701|Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT00054808|Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00057447|Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT00061425|Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00062894|Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00066092|Pegfilgrastim PBPC Mobilization Study|COMPLETED|PHASE2|INTERVENTIONAL","NCT00068718|Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00069758|Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00076349|SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00077961|Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT00081783|Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients|UNKNOWN|PHASE2|INTERVENTIONAL","NCT00082888|Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00086034|Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00089284|Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT00089596|Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00096161|Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant|COMPLETED|PHASE2|INTERVENTIONAL","NCT00100477|Use of Topotecan in Patients With Refractory Acute Leukemia|COMPLETED|PHASE2|INTERVENTIONAL","NCT00100737|Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)|TERMINATED|PHASE2|INTERVENTIONAL","NCT00109356|Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT00115193|Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00117455|A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00117897|Treatment for Subjects With Non-Hodgkin's Lymphoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00120198|Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients|TERMINATED|PHASE2|INTERVENTIONAL"]}]}